OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain TrialTip Ranks·1 day ago, 11:27 AMOKYO+4.73%
OKYO Pharma Announces Purchase of Shares by Chief Executive OfficerUnusual Whales·2 days ago, 06:02 AMOKYO+4.73%
OKYO Pharma Announces Purchase of Shares by Director | OKYO Stock NewsStockTitan·2 days ago, 03:00 AMOKYO+4.73%
OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP TrialTip Ranks·2 days ago, 09:27 AMOKYO+4.73%
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director | OKYO Stock NewsStockTitan·Jul 22 at 01:00 AMOKYO+4.73%
OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod TrialTip Ranks·Jul 21 at 08:30 AMOKYO+4.73%
OKYO Pharma chairman raises stake to 20.51% after buying 25,000 shares at $ 1.4PUBT·Jul 21 at 06:00 AMOKYO+4.73%
OKYO Pharma (NASDAQ:OKYO) Posts Earnings Results, Misses Estimates By $5.45 EPSMarket Beat·Jul 20 at 11:26 AMOKYO+4.73%
OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE TrialTip Ranks·Jul 20 at 06:57 AMOKYO+4.73%
